Skip to main content

Table 2 Results of randomized placebo-controlled clinical trials with CGRP mAb for the treatment of chronic migraine

From: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

 

Phase

Exclusion by unremitting headaches

Exclusion by failed preventives

Study duration (weeks)

Treatment arms

N

MMD change versus placebo

Number of dropouts

Dropout ratio

Reference

Acronym/NCT

Eptinezumab

II

-

-

12

placebo

121

 

0

0%

Dodick et al, 2019

NCT02275117

100mg

123

-2.1

2

2%

300mg

120

-2.6

4

3%

III

+

-

12

placebo

366

 

2

1%

Lipton et al, 2020

PROMISE-2

100mg

356

-2.0

3

1%

300mg

350

-2.6

8

2%

Fremanezumab

II

-

≥3

12

placebo

89

 

1

1%

Bigal et al, 2015

NCT02021773

225mg (a675mg)

88

-1.7

4

5%

900mg monthly

86

-2.0

3

3%

III

+

≥2

12

placebo

375

 

8

2%

Silberstein et al, 2017

HALO

675mg

376

-1.7

5

1%

225mg (a675mg)

379

-1.8

7

2%

II/III

+

≥2

12

placebo

191

 

3

2%

Sakai et al, 2021

NCT03303079

675mg

191

-1.3

1

1%

225mg

189

-2.1

0

0%

Galcanezumab

III

+

>3

12

placebo

558

 

6

1%

Detke et al, 2018

REGAIN

120mg (a240mg)

278

-2.1

3

1%

240mg

277

-1.9

2

1%

Erenumab

II

+

>3

12

placebo

282

 

2

1%

Tepper et al, 2017

NCT02066415

70mg

190

-2.4

0

0%

140mg

188

-2.4

2

1%

  1. Unless indicated differently, dosing is monthly for erenumab, galcanezumab and fremanezumab 225mg and every 3 months for eptinezumab and fremanezumab 675mg
  2. MMD monthly migraine days (for the group average MMD reduction only dosages in bold were used)
  3. aloading dosage